Prevalence and Management of Nephroptosis: A 13-Year Retrospective Study in Kyrgyzstan-Scilight

Trends in Immunotherapy

Article

Prevalence and Management of Nephroptosis: A 13-Year Retrospective Study in Kyrgyzstan

Downloads

https://doi.org/10.54963/ti.v9i2.1114
Chyngyz Imanaliev, Guliya Sadybakasova, Tugolbai Tagaev, Ramil Aliev, Mirbek Baisalov, & Azamat Makambaev. (2025). Prevalence and Management of Nephroptosis: A 13-Year Retrospective Study in Kyrgyzstan. Trends in Immunotherapy, 9(2), 84–94. https://doi.org/10.54963/ti.v9i2.1114
Volume 9 Issue 2 ( 2025)
Copyright (c) 2025 Chyngyz Imanaliev, Guliya Sadybakasova, Tugolbai Tagaev, Ramil Aliev, Mirbek Baisalov, Azamat Makambaev
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Chyngyz Imanaliev

    Department of Urology, DOC University Clinic, Salymbekov University, Bishkek 760000, Kyrgyzstan
  • Guliya Sadybakasova

    Department of Microbiology, Salymbekov University, Bishkek 720054, Kyrgyzstan
  • Tugolbai Tagaev

    Department of Hospital Internal Medicine, Occupational Pathology with a Course of Hematology, I. K. Akhunbaev Kyrgyz State Medical Academy, Bishkek 720020, Kyrgyzstan
  • Ramil Aliev

    Department of Urology, Kyrgyz‑Russian Slavic University Named after B. N. Yeltsin, Bishkek 720020, Kyrgyzstan
  • Mirbek Baisalov

    Department of Urology, I. K. Akhunbaev Kyrgyz State Medical Academy, Bishkek 720020, Kyrgyzstan
  • Azamat Makambaev

    Department of Urology, Salymbekov University, Bishkek 720054, Kyrgyzstan

Received: 21 March 2025; Revised: 9 May 2025; Accepted: 23 May 2025; Published: 6 June 2025

Nephroptosis (NP) is characterized by abnormal downward displacement of the kidney, predominantly affecting young working women aged 20–45 years. This retrospective observational study aimed to investigate the epidemiology, clinical manifestations, and treatment outcomes of NP in the Kyrgyz Republic between 2010 and 2023. Data from 1824 patients diagnosed with NP in various healthcare institutions were analyzed. NP occurred more frequently in women (79.6%) than in men (20.4%), with Bishkek showing the highest occurrence at 51.4%. Between 2020-2023, the NP incidence increased by 2.8%, and the most common associated conditions were LN (18.5%), hypertension (17.9%), and dyslipidemia (15.7%). In 205 patients with NP and LN, immunosuppressant treatment with prednisone and cyclophosphamide improved kidney function (eGFR increased from 65.8 ± 9.2 to 81.1 ± 7.4 mL/min/1.73 m²; p < 0.01) and reduced proteinuria (from 2.9 ± 1.3 to 0.8 ± 0.4 g/day; p < 0.001) over 12 months. However, 17.5% of patients required surgical nephropexy due to ongoing symptoms. The rising incidence of NPs in Kyrgyzstan emphasizes the need for enhanced diagnostic methods and clinical awareness. The common occurrence of NP with LN highlights the need for multidisciplinary management. While immunosuppressive therapy is effective for NP with LN, some patients benefit from surgical nephropexy. Future studies are needed to assess outcomes and improve treatment strategies, especially in patients with autoimmune diseases.

Keywords:

Nephroptosis; Prevalence; Nephropexy; Lupus Nephritis; Epidemiology; Immunosuppressive Therapy; Prednisone; Cyclophosphamide

References

  1. Kumar, R.; Gupta, R.; Reddy, S.N.; et al. Nephroptosis: the Tc-99m glucoheptonate scan as a diagnostic method. Clin. Nucl. Med. 2000, 25, 473.
  2. Wang, K.; Fan, M.; Shao, F.; et al. Nephroptosis Incidentally Found on 99m Tc-DTPA Renal Dynamic Scan. Clin. Nucl. Med. 2022, 47, 1099–1100.
  3. Murari, S. B.; Gadepalli, T.; Rao, V. P.; et al. Renal scintigraphy in diagnosis and management of nephroptosis. Indian J. Nucl. Med. 2012, 27, 52–54.
  4. Golab, A.; Slojewski, M.; Gliniewicz, B.; et al. Retroperitoneoscopic nephropexy in the treatment of symptomatic nephroptosis with 2-point renal fixation. Surg. Laparosc. Endosc. Percutan Tech. 2009, 19, 356–359.
  5. Gyftopoulos, K.I.; Fokaefs, E.; Barbalias, G.A. The use of the tissue adhesive enbucrilate (histoacryl) in the treatment of symptomatic nephroptosis. Urol. Int. 2002, 69, 313–317.
  6. Bansal, D.; Defoor, W.R., Jr.; Noh, P.H. Pediatric robotic assisted laparoscopic nephropexy: case study. Springerplus 2013, 2, 321.
  7. Rassweiler, J.J.; Frede, T.; Recker, F.; et al. Retroperitoneal laparoscopic nephropexy. Urol. Clin. N. Am. 2001, 28, 137–144.
  8. Philippou, P.; Michalakis, A.; Ioannou, K.; et al. Laparoscopic Nephropexy: The Sliding Clip Technique. J. Endourol. Case Rep. 2020, 6, 224–227.
  9. Mogorovich, A.; Selli, C.; De Maria, M.; et al. Clinical reappraisal and state of the art of nephropexy. Urologia 2018, 85, 135–144.
  10. Ichikawa, T.; Yamada, D.; Takao, A.; et al. Retroperitoneoscopic nephropexy for symptomatic nephroptosis. J. Endourol. 2003, 17, 767–770.
  11. McDougall, E.M.; Afane, J.S.; Dunn, M.D.; et al. Laparoscopic nephropexy: long-term follow-up--Washington University experience. J. Endourol. 2000, 14, 247–250.
  12. Boccardo, G. Hematuria in nephroptosis. Nephron 1998, 79, 113–114.
  13. Ghanem, A.N. Features and complications of nephroptosis causing the loin pain and hematuria syndrome. A preliminary report. Saudi Med. J. 2002, 23, 197–205.
  14. Matsui, Y.; Matsuta, Y.; Okubo, K.; Yoshimura, K.; Terai, A.; Arai, Y. Laparoscopic nephropexy: treatment outcome and quality of life. Int. J. Urol. 2004, 11, 1–6.
  15. Oliva-Pascual-Vaca, Á.; Castillo-Cañuelo, M.J.; Oliva-Pascual-Vaca, J.; et al. A Systematic Review on Spinal Asymmetries in Case Studies of Unilateral Nephroptosis from a Viscerosomatic Point of View. Healthcare 2022, 10, 2422.
  16. Tojo, A.; Onozato, M.L.; Asaba, K.; et al. Spironolactone with ACE inhibitor is effective in gross hematuria caused by nephroptosis. Int. J. Urol. 2006, 13, 990–992.
  17. Gourley, M.F.; Austin, H.A., 3rd.; Scott, D.; et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann. Intern. Med. 1996, 125, 549–557.
  18. Donadio, J.V., Jr.; Holley, K.E.; Ferguson, R.H.; et al. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N. Engl. J. Med. 1978, 299, 1151–1155.
  19. Li, G.; Quan, C.; Niu, Y. AB186. Laparoscopic nephropexy using a self-designed polytetrafluoroethylene “basket”. Transl. Androl. Urol. 2016, 5, AB186.
  20. Yung, S.; Chan, T.M. Mechanisms of Kidney Injury in Lupus Nephritis - the Role of Anti-dsDNA Antibodies. Front. Immunol. 2015, 6, 475.
  21. Jing, C.; Castro-Dopico, T.; Richoz, N.; et al. Macrophage metabolic reprogramming presents a therapeutic target in lupus nephritis. Proc. Natl. Acad. Sci. USA 2020, 117, 15160–15171.
  22. Smita, S.; Chikina, M.; Shlomchik, M.J.; et al. Heterogeneity and clonality of kidney-infiltrating T cells in murine lupus nephritis. JCI Insight 2022, 7, e156048.
  23. Chernova, I.; Song, W.; Steach, H.; et al. The ion transporter Na+-K+-ATPase enables pathological B cell survival in the kidney microenvironment of lupus nephritis. Sci. Adv. 2023, 9, eadf8156.
  24. Benchetrit, S.; Bar-Ziv, D.; Kabaha, M.; et al. #1386 Hypertension is associated with deterioration of kidney function among patients with systemic lupus erythematosus, with or without lupus nephritis. Nephrol. Dial. Transpl. 2024, 39, gfae069–1261–1386.
  25. Boesen, E.I.; Kakalij, R.M. Autoimmune-mediated renal disease and hypertension. Clin. Sci. 2021, 135, 2165–2196.
  26. Mok, C.C. Understanding lupus nephritis: diagnosis, management, and treatment options. Int. J. Womens Health 2012, 4, 213–222.
  27. Mok, C.C.; Tse, S.M.; Chan, K.L.; et al. Prevalence and risk factors of herpes zoster infection in patients with biopsy proven lupus nephritis undergoing immunosuppressive therapies. Lupus 2020, 29, 836–844.
  28. Khan, S.Q.; Khan, I.; Gupta, V. CD11b Activity Modulates Pathogenesis of Lupus Nephritis. Front. Med. 2018, 5, 52.
  29. Contreras, G.; Pardo, V.; Leclercq, B.; et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 2004, 350, 971–980.
  30. Davidson, A.; Aranow, C.; Mackay, M. Lupus nephritis: challenges and progress. Curr. Opin. Rheumatol. 2019, 31, 682–688.
  31. Ward, M.; Tektonidou, M.G. Belimumab as Add-on Therapy in Lupus Nephritis. N. Engl. J. Med. 2020, 383, 1184–1185.
  32. Wang, M.; Rajkumar, S.; Lai, Y.; et al. Tertiary lymphoid structures as local perpetuators of organ-specific immune injury: implication for lupus nephritis. Front. Immunol. 2023, 14, 1204777.
  33. Urban, D.A.; Clayman, R.V.; Kerbl, K.; et al. Laparoscopic nephropexy for symptomatic nephroptosis: initial case report. J. Endourol. 1993, 7, 27–30.
  34. Clayman, R.V.; Kavoussi, L.R.; Soper, N.J.; et al. Laparoscopic nephrectomy. N. Engl. J. Med. 1991, 324, 1370–1371.
  35. Rehman, J.; Hoenig, D.M. Laparoscopic nephropexy. J. Endourol. 2000, 14, 881–888.
  36. Al-Hazmi, H.; Peycelon, M.; Carricaburu, E.; et al. Redo Laparoscopic Pyeloplasty in Infants and Children: Feasible and Effective. Front. Pediatr. 2020, 8, 546741.
  37. Schwartz, N.; Goilav, B.; Putterman, C. The pathogenesis, diagnosis and treatment of lupus nephritis. Curr. Opin. Rheumatol. 2014, 26, 502–509.
  38. Chang, A.; Clark, M.R.; Ko, K. Cellular aspects of the pathogenesis of lupus nephritis. Curr. Opin. Rheumatol. 2021, 33, 197–204.